242. Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.
作者: Brian G Feagan.;William J Sandborn.;Christopher Gasink.;Douglas Jacobstein.;Yinghua Lang.;Joshua R Friedman.;Marion A Blank.;Jewel Johanns.;Long-Long Gao.;Ye Miao.;Omoniyi J Adedokun.;Bruce E Sands.;Stephen B Hanauer.;Severine Vermeire.;Stephan Targan.;Subrata Ghosh.;Willem J de Villiers.;Jean-Frédéric Colombel.;Zsolt Tulassay.;Ursula Seidler.;Bruce A Salzberg.;Pierre Desreumaux.;Scott D Lee.;Edward V Loftus.;Levinus A Dieleman.;Seymour Katz.;Paul Rutgeerts.; .
来源: N Engl J Med. 2016年375卷20期1946-1960页
Ustekinumab, a monoclonal antibody to the p40 subunit of interleukin-12 and interleukin-23, was evaluated as an intravenous induction therapy in two populations with moderately to severely active Crohn's disease. Ustekinumab was also evaluated as subcutaneous maintenance therapy.
|